Reference:
Abara, W. E., Gee, J., Marquez, P., Woo, J., Myers, T. R., DeSantis, A., Baumblatt, J. A. G., Woo, E. J., Thompson, D., Nair, N., Su, J. R., Shimabukuro, T. T., & Shay, D. K. (2023). Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Network Open, 6(2), e2253845. https://doi.org/10.1001/jamanetworkopen.2022.53845
Summary:
This study analysed reports of Guillain-Barré syndrome (GBS) following COVID-19 vaccination in the US, focusing on the Ad26.COV2.S, BNT162b2, and mRNA-1273 vaccines. Among over 487 million doses administered, 295 cases of GBS were verified. Notably, the incidence rate of GBS was significantly higher following Ad26.COV2.S vaccination within both 21 and 42 days compared to the mRNA vaccines. Specifically, GBS reporting rates were approximately 9 to 12 times higher after Ad26.COV2.S. No increased risk for GBS was found with BNT162b2 or mRNA-1273 vaccines. The findings suggest a potential association between Ad26.COV2.S vaccination and GBS, leading to recommendations for preferential use of mRNA vaccines in adults.